rFSH (Recombinant Follicle Stimulating Hormone) is used in the treatment of male and female infertility. It stimulates follicular development in women and supports sperm production in men with specific hormonal deficiencies.
Indications
In Women:
- Ovulation Induction in anovulatory infertility
- Controlled Ovarian Stimulation during Assisted Reproductive Technology (ART) procedures such as IVF
- Polycystic Ovary Syndrome (PCOS)-related infertility
In Men:
- Induction of spermatogenesis in men with hypogonadotropic hypogonadism, in combination with hCG
Pharmacology
rFSH is a recombinant DNA-derived form of human Follicle Stimulating Hormone (FSH) produced in genetically engineered Chinese Hamster Ovary (CHO) cells. It acts directly on the ovaries to stimulate follicular growth and maturation in women and on the testes to promote sperm production in men. It contains no luteinizing hormone (LH) activity.
Dosage & Administration
- Administered by slow subcutaneous (SC) injection.
- Dosage should be individualized according to patient response and monitored through ultrasound and hormone assessments.
Women
- Ovulation induction: Usually starts at 75 IU daily.
- ART cycles: Usually 150-300 IU daily initially.
- PCOS: Generally starts with 75 IU daily and adjusted gradually according to ovarian response.
Men
- hCG pretreatment is required.
- Following testosterone normalization, rFSH is administered at 300 IU weekly (divided doses) along with hCG.
Side Effects
Common and significant side effects may include:
- Pelvic pain
- Abdominal discomfort
- Nausea and vomiting
- Bloating
- Sudden weight gain
- Breathing difficulty
- Ovarian Hyperstimulation Syndrome (OHSS)
- Multiple pregnancy (twins or higher-order pregnancies)
Contraindications
- Pregnancy and breastfeeding
- Primary ovarian failure
- Primary testicular failure
- Tumors of the ovary, breast, uterus, pituitary, or hypothalamus
- Undiagnosed vaginal bleeding
- Hypersensitivity to any component of the product
- Uterine fibroids incompatible with pregnancy